Slingshot Insights | Vstm Overview

VSTM Overview

Upcoming Projects (VSTM)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (VSTM)

Discussing Low-Grade Serous Ovarian Carcinoma (LGSOC) with a specific focus on VS-6766 and trametinib
Tickers: VSTM, NVS
Executed On: Apr 08, 2022 at 11:00 AM EDT

Upcoming & Overdue Catalysts (VSTM)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (VSTM)

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 estimated to complete December 2018
Ticker: VSTM
Occurred on: Dec 11, 2018
NDA Filing for Duvelisib Projected Q1 of 2018
Tickers: VSTM, INFI
Occurred on: Feb 07, 2018
Verastem (VSTM) expects to report top-line data from the Phase 3 DUO Study of duvelisib/ofatumumab infusions in Relapsed or Refractory CLL in mid-year 2017
Ticker: VSTM
Occurred on: Sep 06, 2017
Phase 1/2 initial data of Duvelisib - CONTEMPO trial for treatment-naive patients with follicular lymphoma due 2H 2016 -Study Withdrawn
Tickers: VSTM, INFI
Occurred on: Jun 29, 2016

Strategic Initiatives (VSTM)

Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016